Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Fecal microbiota transplant treats C. difficile in immunocompromised patients

A study in this month's issue of the American Journal of Gastroenterology examines fecal microbiota transplant for the treatment of Clostridium difficile infection in immunocompromised patients.

News image

Patients who are immunocompromised are at increased risk of Clostridium difficile infection (CDI), which has increased to epidemic proportions over the past decade.

Fecal microbiota transplantation (FMT) appears effective for the treatment of Clostridium difficile, although there is concern that immunocompromised patients may be at increased risk of having adverse events related to FMT.

Dr Colleen Kelly and colleagues from Rhode Island, USA describe the multicenter experience of FMT in immunocompromised patients.

A multicenter retrospective series was performed on the use of FMT in immunocompromised patients with Clostridium difficile that was recurrent, refractory, or severe.

The research team described rates of Clostridium difficile cure after FMT as well as adverse events experienced by immunocompromised patients after FMT.

79% were outpatients at the time of FMT
American Journal of Gastroenterology

A 32-item questionnaire soliciting demographic and pre- and post-FMT data was completed for 99 patients at 16 centers, of whom 80 were eligible for inclusion.

Outcomes included rates of Clostridium difficile cure after FMT, serious adverse events such as death or hospitalization within 12 weeks of FMT, infection within 12 weeks of FMT, and adverse events.

Cases included 75 adult and 5 pediatric patients treated with FMT for recurrent, refractory, and severe and/or overlap of recurrent/refractory and severe Clostridium difficile.
 
The team noted that in all, 79% were outpatients at the time of FMT.

The mean follow-up period between FMT and data collection was 11 months.

Reasons for immunocompromise included HIV/AIDS, solid organ transplant, oncologic condition, immunosuppressive therapy for inflammatory bowel disease, and other medical conditions/medications.

The research team found that the Clostridium difficile cure rate after a single FMT was 78%, with 62 patients suffering no recurrence at least 12 weeks post FMT.

The team identified 12 patients who underwent repeat FMT, of whom 8 had no further Clostridium difficile.

Thus, the overall cure rate was 89%.

The researchers found that 15% had any serious adverse event within 12 weeks post FMT, of which 10 were hospitalizations.

The team observed 2 deaths occurred within 12 weeks of FMT, one of which was the result of aspiration during sedation for FMT administered via colonoscopy, and the other was unrelated to FMT.

None suffered infections definitely related to FMT, but 2 patients developed unrelated infections and 5 had self-limited diarrheal illness in which no causal organism was identified.

The team found 1 patient had a superficial mucosal tear caused by the colonoscopy performed for the FMT, and 3 patients reported mild, self-limited abdominal discomfort post FMT.

About 14% of patients experienced disease flare post FMT.

The research team noted 3 ulcerative colitis patients that underwent colectomy related to course of UC >100 days after FMT.

Dr Kelly's team concludes, "This series demonstrates the effective use of FMT for Clostridium difficile in immunocompromized patients with few serious adverse events or related adverse events."

"Importantly, there were no related infectious complications in these high-risk patients."

Am J Gastroenterol 2014; 109:10651071
11 July 2014

Go to top of page Email this page Email this page to a colleague

 28 May 2015

Advanced search
 28 May 2015 
Bleeding and colorectal endoscopic submucosal dissection
 28 May 2015 
Excercise and IBD
 28 May 2015 
Probiotics and Crohn's disease
 27 May 2015 
Management of constipation and IBS
 27 May 2015 
Vegetables and fruit and IBD
 27 May 2015 
Radiofrequency ablation for treatment of GERD
 26 May 2015 
Calcium channel blockers and GI bleeds
 26 May 2015 

Risk factors for celiac disease

 26 May 2015 
Antimicrobials for intraabdominal infection
 25 May 2015 
Risk of GI bleeds with NSAIDs
 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 22 May 2015 
Colonoscopy screening for colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 20 May 2015 
Refractory metastatic colorectal cancer
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 19 May 2015 
Metabolic syndrome and Barrett's
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 18 May 2015 
ESPGHAN celiac guidelines
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Hypnotherapy in IBS/IBD
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us